AMARIN CORPORATION PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.673 USD | -4.51% |
|
-22.20% | -22.64% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 202M 15.89B | Sales 2025 * | 215M 16.89B | Capitalization | 277M 21.74B |
|---|---|---|---|---|---|
| Net income 2024 * | -70M -5.5B | Net income 2025 * | -64M -5.03B | EV / Sales 2024 * | 1.15 x |
| Net cash position 2024 * | 43.92M 3.45B | Net cash position 2025 * | 159M 12.47B | EV / Sales 2025 * | 0.55 x |
| P/E ratio 2024 * |
-3.82
x | P/E ratio 2025 * |
-4.05
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.48% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amarin Corporation plc
More recommendations
More press releases
More news
| 1 day | -4.51% | ||
| 1 week | -22.20% | ||
| Current month | -22.20% | ||
| 1 month | -30.98% | ||
| 3 months | -27.40% | ||
| 6 months | -21.74% | ||
| Current year | -22.64% |
1 week
0.67
0.88
1 month
0.670.96
Current year
0.671.37
1 year
0.651.49
3 years
0.655.97
5 years
0.6526.12
10 years
0.6526.12
| Managers | Title | Age | Since |
|---|---|---|---|
Aaron Berg
CEO | Chief Executive Officer | 61 | 31/10/12 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 19/06/22 |
| Compliance Officer | 55 | 11-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 27/02/23 |
Odysseas Kostas
CHM | Chairman | 49 | 27/02/23 |
Keith Horn
BRD | Director/Board Member | 66 | 27/02/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/06/24 | 0.673 | -4.51% | 3,117,432 |
| 06/06/24 | 0.7048 | -0.45% | 2,212,715 |
| 05/06/24 | 0.708 | +1.14% | 3,538,124 |
| 04/06/24 | 0.7 | -17.91% | 7,914,079 |
| 03/06/24 | 0.8527 | -1.42% | 999,415 |
Delayed Quote Nasdaq, June 07, 2024 at 09:00 pm
More quotes
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Calendar
30/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.673
USD
Average target price
1
USD
Spread / Average Target
+48.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.64% | 277M | |
| +18.72% | 125B | |
| +14.19% | 108B | |
| -4.93% | 24.21B | |
| +3.23% | 22.78B | |
| -10.44% | 17.96B | |
| -41.74% | 16.43B | |
| -13.31% | 16.37B | |
| +2.44% | 13.58B | |
| +27.89% | 11.66B |
- Stock Market
- Equities
- AMRN Stock
